Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ribozyme uses in retinal gene therapy.

W W Hauswirth1, A S Lewin

  • 1Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL 32610, USA.

Progress in Retinal and Eye Research
|October 13, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

miRNA-mediated post-transcriptional silencing of transgenes leads to increased adeno-associated viral vector yield and targeting specificity.

Gene therapy·2017
Same author

Reduced retinal transduction and enhanced transgene-directed immunogenicity with intravitreal delivery of rAAV following posterior vitrectomy in dogs.

Gene therapy·2016
Same author

Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs.

Gene therapy·2016
Same author

Healthy and diseased corticospinal motor neurons are selectively transduced upon direct AAV2-2 injection into the motor cortex.

Gene therapy·2015
Same author

Photoreceptor-targeted gene delivery using intravitreally administered AAV vectors in dogs.

Gene therapy·2015
Same author

AAV8(Y733F)-mediated gene therapy in a Spata7 knockout mouse model of Leber congenital amaurosis and retinitis pigmentosa.

Gene therapy·2015
Same journal

Visual arrestin-1: how did we learn what we know today about this protein?

Progress in retinal and eye research·2026
Same journal

Transcending Genome-Wide Association Studies to Create Useful Multi-omic Views of Glaucoma.

Progress in retinal and eye research·2026
Same journal

Cutting-edge cross-linking biomaterials advancing ophthalmic therapeutics.

Progress in retinal and eye research·2026
Same journal

Scleral remodeling in myopia: mechanisms and therapeutic approaches.

Progress in retinal and eye research·2026
Same journal

Macular fibrosis secondary to neovascular age-related macular degeneration: from clinic to biology.

Progress in retinal and eye research·2026
Same journal

Stromal Transplantation and corneal-sparing techniques in ectatic diseases.

Progress in retinal and eye research·2026
See all related articles

This chapter explores mutation-specific ribozymes for treating inherited retinal diseases. Preclinical testing involves in vitro screening and viral vector delivery for effective gene therapy in animal models.

Area of Science:

  • Molecular Biology
  • Ophthalmology
  • Gene Therapy

Background:

  • Dominantly inherited retinal diseases are a significant cause of vision loss.
  • Current treatments are limited, necessitating novel therapeutic strategies.
  • Ribozymes offer a potential approach for targeted genetic correction.

Purpose of the Study:

  • To discuss the design, delivery, and preclinical testing of mutation-specific ribozymes.
  • To evaluate the suitability of ribozymes for treating inherited retinal diseases.
  • To outline gene therapy approaches for autosomal dominant retinal disease models.

Main Methods:

  • In vitro screening of ribozyme activity in cell-free systems.
  • Survey of viral vector techniques for retinal gene delivery.

Related Experiment Videos

  • Preclinical testing in rodent models of autosomal dominant RP-like disease.

    • Main Results:

    • In vitro activity predicts in vivo efficacy for ribozyme suitability.
    • Viral vector properties must align with ribozyme therapy requirements.
    • Combined therapeutic measures (biochemical, morphological, electrophysiological) are crucial for assessing efficacy.

    Conclusions:

    • Mutation-specific ribozymes show promise for treating inherited retinal diseases.
    • Effective gene delivery is critical for successful ribozyme-based therapy.
    • Further research into alternative ribozyme strategies is warranted for retinal applications.